Valuation : Summit Therapeutics Inc.

Market Cap 801.84Cr 1.08TCr 935.69Cr 880.16Cr 1.51TCr 1,02900Cr 1.52TCr 10TCr 4.05TCr 52TCr 4.07TCr 3.98TCr 1,73600Cr P/E 2026 *
-11.6x
P/E 2027 * -11.6x
Enterprise Value 755.11Cr 1.02TCr 881.16Cr 828.87Cr 1.42TCr 97TCr 1.43TCr 9.8TCr 3.81TCr 49TCr 3.84TCr 3.75TCr 1,63500Cr EV / Sales 2026 *
2,580x
EV / Sales 2027 * 187x
Free-Float
19.11%
Yield 2026 *
-
Yield 2027 * -
1 day+5.47%
1 week+8.08%
Current month+6.02%
1 month+10.69%
3 months-8.08%
6 months-10.81%
Current year-17.44%
1 week 13.37
Extreme 13.37
15.1
1 month 12.07
Extreme 12.07
15.75
Current year 12.07
Extreme 12.07
29.23
1 year 12.07
Extreme 12.07
29.23
3 years 1.52
Extreme 1.52
36.91
5 years 0.66
Extreme 0.66
36.91
10 years 0.66
Extreme 0.66
36.91
Manager TitleAgeSince
Chief Executive Officer 55 25/07/2022
Chief Executive Officer 81 01/04/2020
Director of Finance/CFO 48 02/04/2024
Director TitleAgeSince
Chairman 81 01/02/2020
Director/Board Member 48 01/12/2019
Director/Board Member 55 11/11/2020
Date Insider Type Main position Quantity % Market Cap. Importance
04/06/26 Buy

Chief Executive Officer

1,00,000 0.0129%
04/06/26 Buy

Chief Executive Officer

1,00,000 0.0129%
04/06/26 Buy

Chief Financial Officer

50,000 0.0064%
Change 5-day change 1-year change 3-year change Capi.($)
+5.62%+8.08%-39.43%+785.89% 1.09TCr
-0.25%-0.92%+49.47%+89.45% 6.81TCr
+1.21%+0.80%+46.29%+85.32% 6.36TCr
+1.31%+1.81%+49.04%+12.07% 2.56TCr
-0.94%-2.68%-17.02%+432.55% 2.66TCr
-1.05%-11.67%+0.11%-17.26% 2.55TCr
-6.09%-11.19%+224.80%+351.08% 1.82TCr
+1.18%-2.23%+30.87%-19.04% 1.97TCr
-1.49%-6.35%+7.84%+540.26% 1.52TCr
+2.19%-1.71%+49.95%+145.16% 1.35TCr
Average +0.15%-2.76%+40.19%+240.55% 2.87TCr
Weighted average by Cap. +0.07%-2.49%+42.49%+165.96%

Financials

2026 *2027 *
Net sales 29.26L 39.59L 34.15L 32.12L 55.03L 38Cr 55.33L 3.8Cr 1.48Cr 19Cr 1.49Cr 1.45Cr 63Cr 4.18Cr 5.65Cr 4.87Cr 4.58Cr 7.85Cr 536.28Cr 7.9Cr 54Cr 21Cr 272.8Cr 21Cr 21Cr 904.54Cr
Net income -69Cr -93Cr -81Cr -76Cr -129.86Cr -8.87TCr -130.57Cr -896.16Cr -348.8Cr -4.51TCr -350.76Cr -343.15Cr -15TCr -73Cr -99Cr -85Cr -80Cr -137.36Cr -9.38TCr -138.11Cr -947.91Cr -368.95Cr -4.77TCr -371.01Cr -362.97Cr -16TCr
Net Debt -47Cr -63Cr -55Cr -51Cr -88Cr -6TCr -88Cr -606.39Cr -236.02Cr -3.05TCr -237.34Cr -232.2Cr -10TCr -20Cr -27Cr -23Cr -22Cr -37Cr -2.55TCr -38Cr -257.69Cr -100.3Cr -1.3TCr -100.86Cr -99Cr -4.3TCr
Logo Summit Therapeutics Inc.
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.
Employees
265
Date Price Change Volume
02/26/02 $14.31 +5.03% 27,58,325
31/26/31 $13.62 -0.80% 54,25,208
28/26/28 $13.73 -4.19% 39,06,883
27/26/27 $14.33 +0.70% 48,38,165
26/26/26 $14.23 +6.51% 1,16,34,709
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
10.05GBP
Average target price
21.05GBP
Spread / Average Target
+109.47%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SMMT Stock